Robert Bresnahan's PFE trades
- The latest PFE trade was a purchase on May 15, 2025, when PFE closed at $22.60. It closed at $30.30 on Nov 3, 2026 (+34%).
Price changes use the closing price on each trade date, not the price actually paid, and ignore dividends. Filings report amounts only as ranges, so these figures show direction, not anyone's actual profit.
Robert Bresnahan reported 3 PFE transactions in 3 filings with the House Clerk for 2025–2026: 2 purchases and 1 sale of Pfizer Inc., with trade dates from Feb 25, 2025 to May 15, 2025. The median gap between trade date and filing date is 20 days, and every trade was reported within 45 days.
- 3
- 2 / 1
- $45K – $150K
- 2025-05-31
PFE transactions reported by Robert Bresnahan
| Type | Owner | ||||
|---|---|---|---|---|---|
Pfizer, Inc. Common Stock PFE | Purchase | Self | $15,001 - $50,000 | 2025-05-31 #20030433 | |
Pfizer, Inc. Common Stock PFE | Sale | Self | $15,001 - $50,000 | 2025-04-28 #20030238 | |
Pfizer, Inc. Common Stock PFE | Purchase | Self | $15,001 - $50,000 | 2025-03-27 #20029034 |
A row is a disclosure, not an execution record: the filing reports a date, a bracket, and the reported owner, but not the price, share count, or reason. Compare the trade date with the filing date to see how long the transaction stayed private.
How long disclosure took
Days from trade date to filing date for 3 rows. The STOCK Act allows 30 days from notification and no more than 45 days from the trade. A late row is a timing fact, not evidence of wrongdoing.
- 0–15 days
- 0
- 16–30 days
- 3
- 31–45 days
- 0
- Over 45 days
- 0
- Median / longest
- 20d / 30d
What Robert Bresnahan's PFE filings don’t tell you
A disclosure row records a trade date, an amount bracket, and who owned the asset. It does not say why the trade was made, whether the position is still held, or anything about the business behind the ticker: revenue trends, margins, balance-sheet risk, or valuation. Those answers are in company filings, not congressional ones.
- Pfizer Inc. financials and filings
Audited SEC figures, what moves PFE, and primary sources.
Compare LLY vs PFE side by side
To work through a company yourself, use our stock research checklist. Members get the full version of that work: one sourced investment call a month, with the numbers and the risks that would change the view.
Members-only research
What members are reading this month
- NVIDIA’s growth has a financing bill
Sales up about 18% on the prior quarter, receivables up about 55%, supply commitments at $279 billion. What NVIDIA’s financing bill means for the price you pay.
- Citadel bought the AI fire sale. The seller had run out of time.
Up 439% in the first half, down about 67% in July: how an AI hedge fund ended up selling a roughly $16 billion stock book to Citadel at a discount.
The thesis, the numbers behind it, and what would break it. Full access is $39 a month.
Read the full researchOther members of Congress who reported PFE
More tickers reported by Robert Bresnahan
Robert Bresnahan and PFE: questions
Did Robert Bresnahan buy or sell PFE?
House Clerk filings for 2025 and 2026 show 2 purchases and 1 sale of Pfizer Inc. (PFE) reported by Robert Bresnahan, between 2025-02-25 and 2025-05-15. Reported owner: Self.
How much PFE did Robert Bresnahan trade?
Filings disclose brackets, not exact values. Summing the low and high ends of each bracket gives $45K – $150K across 3 transactions. Yield Theory does not estimate share counts, prices, or gains from these ranges.
When was the last PFE filing by Robert Bresnahan?
The most recent filing that includes a PFE trade was filed on 2025-05-31. New filings appear in the House Clerk index and are picked up when the dataset is refreshed.
Yield Theory is not affiliated with any elected official or with Pfizer Inc.. Rows are parsed from public House Clerk periodic transaction reports; amounts are reported brackets and filings can be amended. This page is educational and is not investment advice.
Don’t copy the filing. Read the thesis.
Robert Bresnahan PFE disclosures are delayed, ranged, and often a spouse. Members get the monthly call that treats those rows as one input, then names catalysts, risks, and what would change the view. $39/month or $249/year.
Members-only research
$39/mo or $249/yr · cancel future renewals anytime · sources included